Case Studies

Our client required support to develop an access strategy to meet EU payer requirements, critical appraisal, evidence generation, value proposition development and HTA submission, for their new product

How do you determine the optimum indication launch sequence for an early-stage (pre-trial) asset?​ Our client was interested in understanding pricing and launch sequencing across 12 indications and 8 countries

Our client was launching a new product into the crowded rheumatoid arthritis (RA) market and needed support to synthesise a comprehensive package of evidence suitable for global reimbursement decisions for the use of an alternative treatment in moderate to severe RA

Health economic evaluations are typically performed at a specific point within a pathway of care. This relatively narrow focus has potential to overlook important consequences to the healthcare system within strategic policy decision-making. HEOR proposed a broader whole-disease approach to assess disease burden and the value of therapeutic innovation

Our clients were preparing for single technology appraisal of their new long-acting formulation drug. The evidence base for the new drug was from non-inferiority studies, which limited the scope for the indirect treatment comparison with comparator treatments required by NICE to inform comparative effectiveness

There is a lack of awareness of the CKD indication for SGLT2 inhibitors. Our client wanted to address the knowledge gap in order to encourage greater and safe use of these drugs which may offer significant clinical benefits for patients

A complex commercial deal was agreed between the NHS and our client’s competitor and our client wanted to understand the implications of the deal for their current pipeline and any opportunities for potential future commercial deals

Our client, who market a direct oral anticoagulant (DOAC), wanted to develop a method to accurately predict which patients are likely to have suboptimal warfarin control and may be better suited to DOAC therapy